Tesamorelin: FDA-Approved GHRH Analogue for Visceral Fat and Metabolic Health

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone — the only GHRH analogue with FDA approval. Its design confers resistance to enzymatic breakdown, dramatically extending its half-life and producing clinically meaningful reductions in visceral adipose tissue.

By UAE Peptide Clinic Research Desk

Tesamorelin is a 44-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH). Its design includes a specific N-terminal modification — a trans-3-hexenoic acid group — that confers resistance to the enzyme dipeptidyl peptidase IV (DPP-IV), dramatically extending its half-life compared to native GHRH. It is the only GHRH analogue with FDA approval, indicated for HIV-associated lipodystrophy and the selective reduction of visceral adipose tissue.

Mechanism of Action

Tesamorelin binds to the GHRH receptor on pituitary somatotrophs and stimulates the release of endogenous growth hormone. The downstream effect is an elevation of circulating IGF-1 and, through IGF-1 signalling, selective reduction of visceral (intra-abdominal) fat. Unlike growth hormone itself, Tesamorelin works through the body's own feedback mechanisms, maintaining a more physiological response pattern with reduced risk of adverse effects associated with direct GH administration.

Clinical Applications and Evidence

In clinical trials, Tesamorelin produced visceral fat reductions of 15 to 20% over 26 weeks, with modest but measurable improvements in lipid profiles. Off-label research has examined its role in non-alcoholic fatty liver disease, age-related metabolic decline, and cognitive function in older adults. It is most appropriate for patients with documented central adiposity and evidence of somatotropic axis decline.

• Available formats: Vial (2 options)
• FDA-approved for HIV-associated lipodystrophy
• Visceral fat reduction of 15-20% in clinical trials
• IGF-1 monitoring required throughout protocol

Tesamorelin is available at UAE Peptide Clinic for patients with appropriate clinical indications. Our physicians will review your metabolic panel and body composition data before recommending. Explore the protocol at /peptides/tesamorelin or book a consultation at /book.